Clinical trials: IBS (Irritable Bowel Syndrome)
Irritable Bowel Syndrome
Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)
Participants with IBS (all subtypes) and with no exclusionary comorbid psychiatric or medical disorders will be enrolled in the study.
- Trial name
- NCT06206265
- Testing
- TRYP-0082, Psychotherapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- TRYP Therapeutics
Constipation Predominant Irritable Bowel Syndrome
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
This phase 3, 12-week, randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of tenapanor in subjects with constipation-predominant irritable bowel syndrome (IBS-C) as defined by…
- Trial name
- T3MPO-1 (NCT02621892)
- Testing
- Tenapanor
- Where
- 111 sites in United States
- Volunteers
- 606 people
- Sponsor
- Ardelyx
Diarrhea-predominant Irritable Bowel Syndrome
Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
This study is being conducted to evaluate in participants with diarrhea-predominant Irritable Bowel Syndrome (IBS-D) the abdominal pain response to BOS-589 after 4 weeks of treatment and to evaluate the overall safety and…
- Trial name
- NCT03977155
- Testing
- BOS-589
- Where
- 58 sites in United States
- Volunteers
- 133 people
- Sponsor
- Boston Pharmaceuticals
Irritable Bowel Syndrome, Wheat Sensitivity
Effects of Wheat Breads on Symptoms of IBS, a Pilot Study
This is randomized pilot study comparing tolerability of yeast-baked wheat bread and sourdough wheat bread in irritable bowel syndrome.
- Trial name
- Wheat-IBS (NCT02572908)
- Testing
- Sourdough wheat bread, Regular yeast baked toast bread, Gluten-free diet
- Where
- Finland
- Volunteers
- 26 people
- Sponsor
- Oy Karl Fazer Ab
Irritable Bowel Syndrome
Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
This study will evaluate the tolerability, safety and efficacy of DNK333 against diarrhea caused by Irritable Bowel Syndrome in women.
- Trial name
- CDNK333B2201 (NCT00699166)
- Testing
- DNK333
- Where
- 29 sites in United States
- Volunteers
- 135 people
- Sponsor
- Novartis
Irritable Bowel Syndrome, Digestive System Diseases
Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)
The purpose of this study is to compare the effects of 5g of Daikenchuto (TU-100) three times per day (Daikenchuto [TU-100] is a botanical agent that modulates gastrointestinal nerves), and placebo on rectal sensation (sensation…
- Conditions
- Irritable Bowel Syndrome, Digestive System Diseases, Gastrointestinal Diseases, Intestinal Diseases
- Trial name
- NCT01890837
- Testing
- Daikenchuto (TU-100)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Tsumura USA
Constipation Predominant Irritable Bowel Syndrome
A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C
This phase 3, open label study will evaluate the safety of tenapanor 50 mg BID in subjects with constipation-predominant irritable bowel syndrome (IBS-C) defined by the ROME III criteria.
- Trial name
- T3MPO-3 (NCT02727751)
- Testing
- Tenapanor
- Where
- United States
- Volunteers
- 312 people
- Sponsor
- Ardelyx
Irritable Bowel Syndrome With Diarrhea
Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use
This study will evaluate the efficacy and safety of eluxadoline 100 milligrams (mg) twice a day (BID) versus placebo for the treatment of patients with Irritable Bowel Syndrome with Diarrhea (IBS-D) who report that the use of…
- Trial name
- NCT02959983
- Testing
- Eluxadoline
- Where
- 83 sites in United States, Canada
- Volunteers
- 346 people
- Sponsor
- Allergan
Rheumatoid Arthritis, Diabetic Neuropathy
Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training
CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a multimodal treatment in supplementary or standalone prescription or nonprescription software-based digital…
- Conditions
- Rheumatoid Arthritis, Diabetic Neuropathy, Fibromyalgia, Irritable Bowel Syndrome
- Trial name
- NCT05573685
- Testing
- DiNaMo Study App
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Click Therapeutics, Inc.
Crohn's Disease
Long-term Safety Study of Brodalumab in Adults With Crohn's Disease
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with brodalumab in adults with Crohn's disease.
- Trial name
- NCT01199302
- Testing
- Brodalumab
- Where
- 34 sites in United States, Australia and 6 more
- Volunteers
- 67 people
- Sponsor
- Amgen
Irritable Bowel Syndrome (IBS)
A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers
This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, retards the emptying of the colon and increases total colonic transit time.
- Trial name
- NCT00401479
- Testing
- Solabegron (GW427353)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome (IBS)
Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
The objective is to evaluate whether ONO-2952 modulates visceral pain perception produced by rectal distention in female patients with IBS-D
- Trial name
- RESTORE (NCT01887002)
- Testing
- ONO-2952
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Ono Pharma USA Inc
Irritable Bowel Syndrome
Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS
The primary objective of this trial is to compare the dose-ranging pharmacodynamic effects of orally administered placebo, and 100 and 1000 ug qd of MD-1100 Acetate on gastrointestinal transit in patients with C-IBS.
- Trial name
- NCT00258193
- Testing
- MD-1100 Acetate
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel…
- Trial name
- NCT01553591
- Testing
- Eluxadoline
- Where
- 283 sites in United States, Canada and 1 more
- Volunteers
- 1,282 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Irritable Bowel Syndrome
A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome
The purpose of this study is to explore and examine endpoints that allow evaluation of the "clinically significant improvements, focusing on the patient's chief complaint and the severity of major IBS symptoms" by this drug in…
- Trial name
- NCT00918411
- Testing
- Ramosetron
- Where
- 4 sites in Japan
- Volunteers
- 98 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome With Constipation (IBS-C)
Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C
Open-label long-term safety study of tenapanor in pediatric patients with IBS-C.
- Trial name
- NCT05905926
- Testing
- Tenapanor
- Where
- 27 sites in United States
- Volunteers
- 150 people
- Sponsor
- Ardelyx
Irritable Bowel Syndrome
A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
This study will examine the efficacy, safety and tolerability of different oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.
- Trial name
- NCT00189813
- Testing
- YM060
- Where
- 45 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 691 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome with Diarrhea
Efficacy and Safety of Changkang Granule in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
The aim of this study is to evaluate the efficacy and safety of Changkang granule as compared to placebo over a 8-week treatment period and explore TCM syndrome types.
- Trial name
- NCT04492787
- Testing
- Changkang Granule
- Where
- 8 sites in China
- Volunteers
- 240 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Irritable Bowel Syndrome (IBS), Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS) is one of the major Disorders of Gut-Brain Interaction (DGBI) and the most frequent reasons for referral to both primary care providers and gastroenterologists.IBS is not a life-threatening disease…
- Trial name
- GIANT (NCT06681012)
- Testing
- Gelsectan®
- Where
- 12 sites in Belgium, France and 2 more
- Volunteers
- 330 people
- Sponsor
- Devintec Sagl
Irritable Bowel Syndrome
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
The primary objectives of this study are to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea (IBS-D) in pediatric participants 6-17 years of age, to evaluate the pharmacokinetics of…
- Trial name
- NCT03339128
- Testing
- Eluxadoline
- Where
- 46 sites in United States, Bulgaria and 7 more
- Volunteers
- 272 people
- Sponsor
- AbbVie